Publicaciones en colaboración con investigadores/as de University of Würzburg (37)

2023

  1. Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma

    Communications Biology, Vol. 6, Núm. 1

  2. Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 1, pp. 279-288

2022

  1. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

    Journal of the National Cancer Institute, Vol. 114, Núm. 1, pp. 109-122

  2. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

    Communications biology, Vol. 5, Núm. 1, pp. 1061

2021

  1. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

    Nature Communications, Vol. 12, Núm. 1

  2. Cereblon enhancer methylation and IMiD resistance in multiple myeloma

    Blood, Vol. 138, Núm. 18, pp. 1721-1726

  3. Erratum: Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature communications (2021) 12 1 (1078))

    Nature communications

  4. Large between-patient variability in egfr decline before clinical trial enrollment and impact on atrasentan’s efficacy: a post hoc analysis from the SONAR trial

    Journal of the American Society of Nephrology, Vol. 32, Núm. 11, pp. 2731-2734

  5. Prevalence and early-life risk factors of school-age allergic multimorbidity: The EuroPrevall-iFAAM birth cohort

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 9, pp. 2855-2865

  6. Primary and pollen-associated hazelnut allergy in school-aged children in Germany: A birth cohort study

    Allergology International, Vol. 70, Núm. 4, pp. 463-470

  7. Primary cutaneous peripheral T-cell lymphoma, not otherwise specified: results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinico-pathological and prognostic features

    Journal of the European Academy of Dermatology and Venereology, Vol. 35, Núm. 3, pp. 658-668

2020

  1. Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness

    Cancer Research, Vol. 80, Núm. 3, pp. 624-638

  2. Frequency of food allergy in school-aged children in eight European countries—The EuroPrevall-iFAAM birth cohort

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 9, pp. 2294-2308

  3. IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma

    Haematologica

  4. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

    The Lancet Oncology, Vol. 21, Núm. 1, pp. 105-120

2019

  1. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

    Nature Communications, Vol. 10, Núm. 1

  2. Hierarchy of mono- And biallelic TP53 alterations in multiple myeloma cell fitness

    Blood

  3. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification

    Human Mutation, Vol. 40, Núm. 9, pp. 1557-1578

  4. Spectrum and functional validation of PSMB5 mutations in multiple myeloma

    Leukemia, Vol. 33, Núm. 2, pp. 447-456

  5. Two truncating variants in FANCC and breast cancer risk

    Scientific Reports, Vol. 9, Núm. 1